Acquired drug resistance conferred by a KRAS gene mutation following the administration of cetuximab: a case report [PDF]
, 2013 BACKGROUND: Although a number of studies have reported acquired drug resistance due to administration of epidermal growth factor receptor antibody inhibitors, the underlying causes of this phenomenon remain unclear.
Akio Saiura +8 more
core +1 more source
Epidermal Growth Factor Receptor Pathway [PDF]
Journal of Thoracic Oncology, 2010 The epidermal growth factor receptor (EGFR) pathway has provided a new therapeutic target in non-small cell lung cancer (NSCLC). Two EGFR tyrosine kinase inhibitors (TKIs) are being used globally as systemic treatment in advanced NSCLC. In addition, clinical observations with EGFR TKIS led to the discovery of EGFR activating mutations, which has ...
openaire +2 more sources
Journal of Cosmetic Dermatology, 2020 AbstractBackgroundEpidermal growth factor receptor inhibitors (EGFRI) used in cancer chemotherapy cause acneiform folliculitis in 70%‐100% of patients in a dose‐dependent manner. Acneiform folliculitis is considered to be caused by an inflammatory process due to follicular hyperkeratosis and subsequently a set of changes both in epidermis and hair ...
Ikbal Esen Aydingoz +4 more
openaire +4 more sources
Tumor Biology, 2017 Gallbladder cancer has poor prognosis and limited therapeutic options. Arctigenin, a representative dibenzylbutyrolactone lignan, occurs in a variety of plants.
Mingdi Zhang +11 more
doaj +1 more source
The clinical effectiveness and cost-effectiveness of cetuximab (mono- or combination chemotherapy), bevacizumab (combination with non-oxaliplatin chemotherapy) and panitumumab (monotherapy) for the treatment of metastatic colorectal cancer after first-line chemotherapy (review of technology appraisal No.150 and part review of technology appraisal No. 118): a systematic review and economic model [PDF]
, 2013 Colorectal cancer is the third most commonly diagnosed cancer in the UK after breast and lung cancer. People with metastatic disease who are sufficiently fit are usually treated with active chemotherapy as first- or second-line therapy.
Cooper, Chris +7 more
core +2 more sources
Epidermal growth factor as a biologic switch in hair growth cycle [PDF]
, 2002 The hair growth cycle consists of three stages known as the anagen (growing), catagen (involution), and telogen (resting) phases. This cyclical growth of hair is regulated by a diversity of growth factors.
Chan, SY, Mak, KKL
core +1 more source
Effects of EGFR Expression on Anti-tumor Efficacy of Vandetanib or Cediranib Combined with Radiotherapy (RT) in U87 Human Glioblastoma (GBM) Xenografts [PDF]
, 2010 Introduction: Vandetanib is a receptor tyrosine kinase inhibitor (RTKI) with activity against vascular endothelial growth factor receptor-2 (VEGFR-2) and epidermal growth factor receptor (EGFR).
Dicker, A. P. +3 more
core +2 more sources
BMC Medical Imaging, 2021 Background Human epidermal growth factor receptor2+ subtype breast cancer has a high degree of malignancy and a poor prognosis. The aim of this study is to develop a prediction model for the human epidermal growth factor receptor2+ subtype (non-luminal ...
Jin Zhou +9 more
doaj +1 more source
Molecules, 2021 Epidermal growth factor receptor (EGFR) and vascular endothelial growth factor receptor (VEGFR) are two extensively studied membrane-bound receptor tyrosine kinase proteins that are frequently overexpressed in many cancers.
Nichole E. M. Kaufman +3 more
doaj +1 more source
Technology in Cancer Research & Treatment, 2020 Background: The efficacy of next-generation epidermal growth factor receptor-tyrosine kinase inhibitors in patients with advanced non-small cell lung cancer who have failed first-generation epidermal growth factor receptor-tyrosine kinase inhibitors ...
Yi-Tian Qi MM +2 more
doaj +1 more source